Log in

NASDAQ:ALNYAlnylam Pharmaceuticals Price Target & Analyst Ratings

$136.69
+0.08 (+0.06 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$135.02
Now: $136.69
$139.40
50-Day Range
$136.61
MA: $152.74
$165.49
52-Week Range
$73.32
Now: $136.69
$167.33
Volume391,500 shs
Average Volume778,354 shs
Market Capitalization$15.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Analyst Ratings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Alnylam Pharmaceuticals in the last 12 months. Their average twelve-month price target is $150.89, suggesting that the stock has a possible upside of 10.39%. The high price target for ALNY is $202.00 and the low price target for ALNY is $74.00. There are currently 1 sell rating, 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.632.722.682.69
Ratings Breakdown: 1 Sell Rating(s)
5 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $150.89$153.33$146.16$129.19
Price Target Upside: 10.39% upside2.48% downside2.62% upside1.76% downside

Alnylam Pharmaceuticals (NASDAQ:ALNY) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2020OppenheimerDowngradeOutperform ➝ Market Perform$162.00 ➝ $156.00Low
8/7/2020Morgan StanleyLower Price TargetOverweight$199.00 ➝ $197.00Low
8/7/2020Chardan CapitalReiterated RatingBuyLow
8/7/2020SVB LeerinkBoost Price TargetMarket Perform$89.00 ➝ $90.00Low
7/20/2020BMO Capital MarketsBoost Price TargetOutperform$173.00 ➝ $196.00High
5/28/2020UBS GroupBoost Price TargetNeutral$111.00 ➝ $122.00Low
5/12/2020Royal Bank of CanadaInitiated CoverageSector Perform$150.00Medium
5/7/2020BarclaysBoost Price TargetOverweight$143.00 ➝ $156.00High
5/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00High
5/6/2020Needham & Company LLCBoost Price TargetBuy$135.00 ➝ $160.00High
4/24/2020Evercore ISIInitiated CoverageBuy$160.00Low
4/14/2020Cantor FitzgeraldBoost Price Target$195.00 ➝ $202.00Low
4/14/2020Piper SandlerLower Price Target$147.00 ➝ $142.00Medium
4/14/2020Nomura SecuritiesLower Price TargetReduce$75.00 ➝ $74.00Medium
3/19/2020Berenberg BankInitiated CoverageBuy$200.00Low
3/5/2020CowenReiterated RatingBuyMedium
12/17/2019Piper Jaffray CompaniesBoost Price TargetOverweight$145.00 ➝ $155.00Medium
11/13/2019Bank of AmericaInitiated CoverageBuy$110.00Low
9/3/2019Stifel NicolausSet Price TargetBuy$116.00Low
5/23/2019Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$80.00Medium
12/17/2018GuggenheimInitiated CoverageBuy$105.00Medium
8/28/2018JMP SecuritiesSet Price TargetBuy$198.00Medium
8/13/2018B. RileyBoost Price TargetBuy ➝ Buy$210.00 ➝ $230.00High
8/6/2018Jefferies Financial GroupReiterated RatingBuy$149.00Low
3/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $154.00High
10/30/2017FBR & CoInitiated CoverageBuy ➝ Buy$150.00N/A
9/21/2017LADENBURG THALM/SH SHReiterated RatingBuy$90.00 ➝ $146.00Low
9/21/2017Sanford C. BernsteinReiterated RatingOutperform ➝ Buy$94.00 ➝ $135.00Low
9/15/2017Nomura InstinetInitiated CoverageReduce ➝ Reduce$56.00Low
(Data available from 8/14/2018 forward)
This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.